EmeritusDX Launches GI Detectâ„¢: A Comprehensive Diagnostic Test for Gastrointestinal Health with Rapid 24-Hour Turnaround

News provided by

EmeritusDX

Nov 14, 2024, 06:00 ET


New Test Detects 26 Bacteria, Viruses, and Parasites in a Single, Simple Stool Swab

LAKE FOREST, Calif., Nov. 14, 2024 /PRNewswire-PRWeb/ -- EmeritusDX, a rapidly growing diagnostics and information company, today announced the launch of GI Detectâ„¢, a laboratory diagnostic test designed to assist healthcare providers in diagnosing gastrointestinal disturbances. This new test utilizes a single stool swab to identify 26 bacteria, viruses, and parasites known to disrupt the digestive system. With a 24-hour turnaround time, GI Detectâ„¢ offers an efficient solution to help healthcare providers make timely, informed decisions.

At EmeritusDX, we are dedicated to our mission, "Together we save lives," and are excited to announce the launch of GI Detect—a groundbreaking diagnostic test poised to make a life-saving difference in the fight against gastrointestinal infections. Clostridium difficile (C. diff), an incredibly infectious diarrheal disease, tragically claims over 14,000 American lives each year, especially impacting those with weakened microbiomes due to antibiotics. C. diff represents just one of many GI pathogens that contribute to the substantial global burden of gastrointestinal disease, responsible for approximately 1.6 million deaths annually. This burden includes deadly bacteria like Escherichia coli and Salmonella, as well as viruses and parasites that devastate vulnerable populations worldwide. Our innovative GI Detect™ test aims to address these life-threatening infections, emphasizing our commitment to improving patient outcomes and saving lives on a global scale

GI Detectâ„¢ covers a comprehensive list of pathogens that can cause gastrointestinal distress, covering key viral, bacterial, and parasitic agents. "The launch of GI Detectâ„¢ demonstrates EmeritusDX's commitment to providing innovative diagnostic solutions that elevate patient care and enable healthcare providers to quickly address gastrointestinal issues," said Robert Embree, Chief Executive Officer of EmeritusDX. "With GI Detectâ„¢, clinicians receive an unparalleled level of precision and speed, which means patients get answers faster and can start on a path to recovery sooner."

The GI Detectâ„¢ Panel Includes:

  • Viruses: Adenovirus F40/41, Astrovirus, Norovirus G1 and G2, Rotavirus A, Saprovirus (Types 1, 2, 4, and 5)
  • Bacteria: Campylobacter (jejuni, upsaliensis, coli), Clostridium difficile (toxin A or B), Plesiomonas shigelloides, Salmonella, Yersinia enterocolitica, E. coli O157
  • Pathogenic E. coli Strains: Enteroaggregative E. coli (EAEC), Enteropathogenic E. coli (EPEC), Enterotoxigenic E. coli (ETEC), Shiga-like toxin-producing E. coli (STEC) with stx1 or sxt2, and Shigella/Enteroinvasive E. coli (EIEC)
  • Helicobacter pylori Strains and Virulence Factors: Helicobacter pylori, Helicobacter pylori (Virulence factors VacA, cagA, and babA)
  • Parasites: Cryptosporidium, Entamoeba histolytica, Giardia lamblia

Vincent Funari, PhD, Chief Scientific Officer at EmeritusDX, emphasized the importance of the test in streamlining diagnostics: "GI Detectâ„¢ provides a robust, highly targeted panel that delivers clear, actionable results within 24 hours. By harnessing advanced detection technology, we can quickly identify a comprehensive list of pathogens, allowing healthcare providers to implement targeted treatment approaches sooner."

The GI Detectâ„¢ test underscores EmeritusDX's commitment to advancing diagnostic accuracy, efficiency, and patient-centered care within the field of gastrointestinal health.

About EmeritusDX

EmeritusDX is a diagnostic and information company. Our expertise is in delivering actionable clinical information. Within our world-class laboratory, we perform testing that guides the diagnosis and treatment of cancer patients. Our partners include hospital and private pathology laboratories, biotechnology companies, academic institutions, contract research and pharmaceutical development organizations, and more. We understand the dependency on our accurate and timely results and our commitment to excellence in this regard is unwavering.

If you would like more information about this topic, please call 800-959-2846 or email [email protected]

Media Contact

Charlie Torano, EmeritusDX, 1 800-959-2846, [email protected],

SOURCE EmeritusDX; EmeritusDX